GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Capex-to-Operating-Income

Cyfuse Biomedical KK (TSE:4892) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Cyfuse Biomedical KK's Capital Expenditure for the three months ended in Dec. 2024 was 円0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was 円0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Cyfuse Biomedical KK Capex-to-Operating-Income Historical Data

The historical data trend for Cyfuse Biomedical KK's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Capex-to-Operating-Income Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
- - - - -

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyfuse Biomedical KK's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Capex-to-Operating-Income falls into.


;
;

Cyfuse Biomedical KK Capex-to-Operating-Income Calculation

Cyfuse Biomedical KK's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-8.546) / -896.133
=N/A

Cyfuse Biomedical KK's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyfuse Biomedical KK  (TSE:4892) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Cyfuse Biomedical KK Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK Headlines

No Headlines